| Old Articles: <Older 7591-7600 Newer> |
|---|
 |
The Motley Fool
June 30, 2011
Brian Orelli |
2 Backdoor Biotech IPOs to Watch Just don't buy yet.   |
The Motley Fool
June 29, 2011
Brian Orelli |
4 Immunotherapies to Watch Just don't go all-in. |
The Motley Fool
June 29, 2011
Seth Jayson |
A Hidden Reason Why the Future Looks Bright for Quidel Quidel seems to be handling inventory well enough, but the individual segments don't provide a clear signal. |
The Motley Fool
June 29, 2011
Brian Orelli |
So Much Insulin, So Little Use for It MannKind settles its supply agreement with Merck. |
The Motley Fool
June 29, 2011
Seth Jayson |
Here's Why Volcano's Latest Report Might Worry You How is Volcano doing by this quick checkup? At first glance, pretty well. |
The Motley Fool
June 29, 2011
Brian Orelli |
Doubling Up in Biotech Lilly hits multiple targets with one drug. |
The Motley Fool
June 28, 2011
Brian Orelli |
HIV Drug Partnership Gets a Boost Gilead and Johnson & Johnson hook up on a pair of new combo treatments. |
CIO
May 31, 2011
Fred O'Connor |
Hospitals Compete for IT Talent with Funding At Stake Health care providers in the U.S. are encountering a lack of qualified candidates as they race to meet federal government deadlines for electronic health record and health IT use. |
Chemistry World
June 28, 2011
Russell Johnson |
Screening for Alzheimer's Drugs in Tandem A simple assay based on sequential enzymatic reactions and a fluorescent sensor could help scientists to discover new Alzheimer's disease drugs. |
The Motley Fool
June 28, 2011
Jordan DiPietro |
Should You Retire With Covidien? Covidien has a beta of 0.82, which is pretty low. Generally speaking, I like to see a beta below 1.2 for retirees, and Covidien fits the bill. |
| <Older 7591-7600 Newer> Return to current articles. |
